Challenges in the pharmacotherapy of the epilepsies

Expert Review of Neurotherapeutics

Volumn 2, Issue 4, 2002, Pages 439-442

  Gatti, Giuliana ^a   Perrucca, Emilio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; VALPROIC ACID; VIGABATRIN;

AFFECTIVE NEUROSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EPILEPSY; GENETIC ANALYSIS; HUMAN; INCOME; INFANTILE SPASM; MORTALITY; NEUROLOGIC DISEASE; PHARMACODYNAMICS; PRESCRIPTION; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT;

EID: 0036307173     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.2.4.439     Document Type: Editorial

References (25)

1. Clinical pharmacology and therapeutic use of the new anti-epileptic drugs
2. Principles of pharmacotherapy of the epilepsies
3. The management of epilepsy in the 1990s: Acquisitions, uncertainties and perspectives for future research
4. Early identification of refractory epilepsy
5. Assessing risk to benefit ratio in anti-epileptic drug therapy
6. The treatment of epilepsy in developing countries: Where do we go from here
7. The treatment gap in epilepsy: The current situation and ways forward
8. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tubeous sclerosis
9. Vigabatrin versus ACTH as first-line treatment for infantile spasms: A randomized, prospective study
10. Novel methods for studying new anti-epileptic drug pharmacology
11. Predicting the response to anti-epileptic drugs: The role of genetic factors
12. Monotherapy trials with the new anti-epileptic drugs: Study designs, practical relevance and ethical implications
13. Visual field defects with vigabatrin: Epidemiology and therapeutic implications
14. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy
15. Management issues for women with epilepsy. A review of the literature
16. Pregnancy registries in epilepsy
17. Carbamazepine toxicity with lamotrigine: Pharmacokinetic or pharmacodynamic interaction?
18. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures. Evidence for a pharmacodynamic interaction
19. Lamotrigine substitution study: Evidence for synergism with sodium valproate
20. Selection of anti-epileptic drug polytherapy based on mechanisms of action: The evidence reviewed
21. The impact of the new anti-epileptic drugs on the prognosis of epilepsy. Seizure freedom should be the ultimate goal
22. Pros and cons for the development of new anti-epileptic drugs
23. Progress report on new anti-epileptic drugs: A summary of the Sixth Eilat Conference (EILAT VI)
24. Anti-epileptogenic agents: How dose are we?
25. Anti-epileptogenesis and seizure prevention trials with anti-epileptic drugs: Metanalysis of controlled trials